HRH4

HRH4 (H4R) is a Gi-coupled histamine receptor that signals primarily in immune and neural cell types to drive inflammatory effector programs (PMID:11118334). Cloned from human leukocytes, it inhibits forskolin-induced cAMP accumulation upon histamine binding, with ligand recognition centered on the orthosteric residues Asp3.32, Glu5.46, and Gln7.42 (PMID:11118334); functional and binding analyses across orthologs and recombinant systems define species-specific affinity determinants and ligand-dependent functional selectivity at the receptor (PMID:20103609, PMID:22033803). In mast cells, H4R activation couples to distinct downstream cascades to direct effector output: ERK1/2 drives RANTES/CCL5 production, Akt drives IL-13, NF-κB-p65 is engaged downstream of histamine, and SAPK/JNK signaling mediates intracellular Ca2+ release, degranulation, and IL-1β release (PMID:27400655, PMID:29863427). The receptor extends this proinflammatory role to the nervous system, where H4R activation in microglia stimulates TNF-α and IL-1β production and microglial activation in vivo (PMID:31863333), yet microglial-specific Hrh4 deletion paradoxically reverses cognitive deficits and reduces Aβ and tau pathology in AD model mice by engaging a cAMP/TGF-β1/Smad3 axis that enhances phagocytosis (PMID:41134085). H4R also functions in non-hematopoietic contexts, activating ERK1/2 in brain endothelial cells (PMID:23488566), modulating cAMP-dependent growth arrest and chemosensitivity in colorectal cancer cells (PMID:21609450), and influencing EMT and proliferation in lung cancer cells in a manner attenuated by the rs11662595 polymorphism that impairs Gi activation (PMID:28847511).

1. 2000 High

   Established the molecular identity and signaling output of HRH4, answering whether the leukocyte-derived receptor was a functional histamine receptor and how it transduces signal.

   Evidence Cloning from human leukocyte cDNA with radioligand binding and cAMP accumulation assays in recombinant cells

   PMID:11118334

   Open questions at the time

   • Did not define native cell-type signaling beyond cAMP
   • Cross-reactivity with H3 agonists left ligand selectivity unresolved
2. 2010 High

   Mapped the structural basis of species-divergent ligand affinity, addressing why pharmacology differs across H4R orthologs.

   Evidence Chimeric human-pig receptor constructs and site-directed mutagenesis with radioligand binding in HEK293T cells

   PMID:20103609

   Open questions at the time

   • Residue mapping did not address downstream signaling consequences
   • No active-state structural model
3. 2011 Medium

   Demonstrated functional selectivity (biased signaling) at H4R, addressing whether binding affinity predicts signaling output.

   Evidence Radioligand binding and steady-state GTPase assays with clozapine in Sf9 insect cells; molecular docking

   PMID:22033803

   Open questions at the time

   • Single-lab, single-study GTPase readout
   • Bias not validated in native cells
4. 2011 Medium

   Revealed a tumor-suppressive role in colorectal cancer, asking whether H4R signaling alters proliferation and drug response.

   Evidence Stable HRH4 transfection in colorectal cancer cells with proliferation, cell-cycle, apoptosis, and cAMP pathway assays

   PMID:21609450

   Open questions at the time

   • Overexpression model may not reflect endogenous receptor levels
   • Mechanism linking cAMP to cell-cycle arrest not fully resolved
5. 2012 Low

   Computationally defined orthosteric binding contacts and an activation-associated conformational change, framing the structural mechanism of recognition.

   Evidence Homology modeling on the H1R crystal structure with molecular dynamics simulation

   PMID:23220277

   Open questions at the time

   • Computational only, no experimental mutagenesis validation
   • Predicted selectivity residues untested functionally
6. 2013 Medium

   Identified H4R-specific ERK1/2 activation in brain endothelial cells, extending receptor function beyond hematopoietic cells.

   Evidence RT-PCR/sequencing and ERK1/2 phosphorylation assays with selective antagonists in RBE4 cells and in vivo

   PMID:23488566

   Open questions at the time

   • Downstream physiological consequence in vasculature unclear
   • G-protein coupling in this context not directly tested
7. 2015 Low

   Resolved the complete histamine binding pathway and key contact residues, refining the recognition mechanism.

   Evidence Unconstrained molecular dynamics simulation of histamine binding to hH4R

   PMID:25677665

   Open questions at the time

   • Computational only, no experimental validation
   • Does not address signaling conformations
8. 2016 Medium

   Dissected branched effector signaling in mast cells, answering which pathway drives which cytokine.

   Evidence H4R siRNA knockdown and pathway-selective inhibitors with phosphoblotting and cytokine ELISA in HMC-1 and CBMCs

   PMID:27400655

   Open questions at the time

   • Single lab
   • Direct receptor-to-kinase coupling steps not defined
9. 2017 Medium

   Linked a natural HRH4 polymorphism to impaired Gi activation and pro-tumor phenotype, connecting genetic variation to function in lung cancer.

   Evidence Wild-type vs. rs11662595 mutant transfection with Gi activation, invasion/proliferation assays, and xenograft model

   PMID:28847511

   Open questions at the time

   • Single lab
   • Clinical relevance of the SNP not established in patient cohorts here
10. 2018 Medium

    Established SAPK/JNK as the route for H4R-driven Ca2+ release, degranulation, and IL-1β in mast cells.

    Evidence H4R siRNA knockdown and JNK inhibitor with phosphoblotting, ELISA, Ca2+ and degranulation assays in HMC-1 cells

    PMID:29863427

    Open questions at the time

    • Single lab
    • Coupling between Gi/cAMP and JNK not mechanistically bridged
11. 2018 Medium

    Provided in vivo genetic evidence that eosinophil H4R contributes to colitis resolution, defining a tissue-level effector role.

    Evidence Adoptive transfer of H4R+/+ vs H4R-/- eosinophils into IL-5-deficient mice in DSS colitis

    PMID:30319608

    Open questions at the time

    • Molecular signaling in eosinophils not delineated
    • Single lab
12. 2019 Medium

    Demonstrated that microglial H4R drives proinflammatory cytokine release in vivo, opposing H2R/H3R.

    Evidence Intracerebroventricular agonist/antagonist injection with Iba1 IHC, flow cytometry, ELISA and qRT-PCR in rat

    PMID:31863333

    Open questions at the time

    • Intracellular signaling pathway not resolved
    • Single lab
13. 2025 High

    Defined cell-type-specific microglial H4R control of AD pathology via a cAMP/TGF-β1/Smad3 phagocytic axis, establishing therapeutic logic of receptor blockade.

    Evidence Conditional microglial Hrh4 knockout, pharmacological rescue with VUF6002, behavioral/transcriptomic/pathology readouts with TGF-βR1 inhibition rescue in 3xTg-AD mice

    PMID:41134085

    Open questions at the time

    • Reconciliation with proinflammatory microglial role not fully resolved
    • Human relevance untested
14. 2022 Medium

    Identified TRPV4 as a Ca2+-entry effector downstream of H4R in lymphatic endothelial cells via a PLA2-dependent mechanism.

    Evidence Ca2+ imaging, TRPV4 blockers, extracellular Ca2+ removal, NFATc1 translocation and cytoskeletal assays with PLA2 inhibition in primary human LECs (preprint)

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • Direct physical coupling of H4R to TRPV4 not shown

• How H4R's dual proinflammatory and protective roles in microglia are reconciled at the signaling level, and how Gi/cAMP coupling bifurcates into the divergent ERK/Akt/JNK/NF-κB and TGF-β1/Smad3 outputs, remains unresolved.
• No experimental structure of active H4R-G-protein complex in the corpus
• Context-dependent switch between inflammatory and phagocytic programs uncharacterized